Clinical Trial

An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis

Enrolling by Invitation Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of the study is to assess the long term safety and tolerability of additional 6-week treatment cycles with rozanolixizumab in pediatric participants with generalized Myasthenia Gravis (gMG) aged ≥2 at the time of the Screening Visit of MG0006.
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2024-08-01; most recent amendment 2026-07-02.
Status change: Not Yet Recruiting → Enrolling by Invitation 2024-10-30
Trial Details
NCT Number NCT06540144
Lead Sponsor UCB Biopharma SRL
Conditions Generalized Myasthenia Gravis
Enrollment 12 participants
Start Date 2024-10-08
Primary Completion 2027-08-17 (estimated)
Study Completion 2027-08-17 (estimated)
Updated on ClinicalTrials.gov 2026-08-14